AIP
KROS icon

Almanack Investment Partners’s Keros Therapeutics KROS Stock Holding History

Almanack Investment Partners’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-884
Closed -$32K – 716
2022
Q3 		$32K Buy
+884
New +$30.6K 0.01% 319

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Almanack Investment Partners's KROS Position: Q4 2022 in Review

Almanack Investment Partners sold out of Keros Therapeutics (KROS) in Q4 2022, closing a stake of 884 shares — an estimated $32K sold.

Almanack Investment Partners first reported a position in KROS in Q3 2022 and held it in 1 quarter. The position peaked at $32K in Q3 2022. 126 funds tracked by Wall St. Rank hold KROS as of Q4 2022.

  • Almanack Investment Partners reported no remaining Keros Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Almanack Investment Partners sold 884 Keros Therapeutics shares in Q4 2022, an estimated $32K.
  • Almanack Investment Partners first reported a position in Keros Therapeutics in Q3 2022 and held it in 1 quarter.
  • Almanack Investment Partners's Keros Therapeutics position peaked at $32K in Q3 2022.
  • 126 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2022.

Based on Almanack Investment Partners's 13F filing for Q4 2022, filed 9 Feb 2023.